Results 191 to 200 of about 58,192 (237)

Reticulated Platelets and an Optimal Model for Differentiating Thrombocytopenia Etiologies

open access: yeseJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Objectives This study aimed to investigate the clinical value of reticulated platelets (RtcPLT) percentage derived from an automated hematology analyzer in differentiating thrombocytopenia due to peripheral etiology from decreased bone marrow production (BME). In addition, a secondary objective was to establish specific reference intervals for
Tung Thanh Tran   +5 more
wiley   +1 more source

Real‐World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild‐Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using US Electronic Health Records

open access: yeseJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Light chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR‐CM) are the most common types of cardiac amyloidosis. Despite similar manifestations, prognosis and treatments are distinct, emphasizing the importance of accurate and timely diagnosis. This retrospective cohort study assessed real‐world diagnostic workups
Muhamed Baljevic   +7 more
wiley   +1 more source

The “5L” framework of diagnostic reasoning: A stepwise scaffold to support clinician educators

open access: yesJournal of Hospital Medicine, Volume 21, Issue 6, Page 665-669, June 2026.
Abstract Diagnostic reasoning (DR) is a core clinical skill, yet its teaching remains variable. We introduce the “5L” framework as a bedside teaching scaffold that gives educators and learners a shared, stepwise set of prompts for DR during individual encounters. By asking, “What's Lethal? What's Likely? What's Logical? What's Lurking?
Olivia Brumfield   +3 more
wiley   +1 more source

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases.
María Larrosa‐García   +10 more
wiley   +1 more source

Group A β-hemolytic streptococcus causing purpura fulminans: two case reports. [PDF]

open access: yesFront Immunol
Alkhatatbeh A   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy